Table 1.
Clinical characteristics of the TCGA-CESC cohort.
| Characteristics | Patients (N = 306) | |
|---|---|---|
| N | % | |
| Gender | ||
| Female | 306 | 100% |
| Stage | ||
| I | 162 | 52.90% |
| II | 69 | 22.50% |
| III | 46 | 15.00% |
| IV | 22 | 7.20% |
| NA | 7 | 2.30% |
| T | ||
| T1 | 140 | 45.80% |
| T2 | 72 | 23.50% |
| T3 | 21 | 6.90% |
| T4 | 10 | 3.30% |
| TIS | 1 | 0.30% |
| TX | 17 | 5.60% |
| NA | 45 | 14.70% |
| N | ||
| N0 | 134 | 43.80% |
| N1 | 61 | 19.90% |
| NX | 66 | 21.60% |
| NA | 45 | 14.70% |
| M | ||
| M0 | 116 | 37.90% |
| M1 | 11 | 3.60% |
| MX | 129 | 42.20% |
| NA | 50 | 16.30% |
| Race | ||
| American Indian or Alaska Native | 7 | 2.30% |
| Asian | 20 | 6.50% |
| Black or African American | 31 | 10.10% |
| Native Hawaiian or other pacific islander | 2 | 0.70% |
| white | 210 | 68.60% |
| NA | 36 | 11.80% |
| Age | ||
| <=50 | 188 | 61.40% |
| > 50 | 118 | 38.60% |
| Vital status | ||
| ALIVE | 233 | 76.10% |
| DEAD | 73 | 23.90% |
| Survival time | ||
| Long(>5yeas) | 47 | 15.40% |
| Short(<5years) | 259 | 84.60% |
TCGA, The Cancer Genome Atlas; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; NA, not applicable.